Table 3

Meta-regression stratified by clinical characteristics to address the effect of ADA on drug response and the effect of IS on ADA detection

Clinical characteristicRR (95% CI)p for interaction
Effect of ADA on response
Imunosupressors, %
 Lower proportion IS (<67%)0.24 (0.11 to 0.53)0.220
 Higher proportion MTX (≥67%)0.40 (0.27 to 0.61)
Methotrexate, %
 Lower proportion MTX (<74%)0.24 (0.14 to 0.40)0.028
 Higher proportion MTX (≥74%)0.50 (0.35 to 0.71)
Primary diagnosis
 RA0.47 (0.33 to 0.65)0.034
 Other diseases0.22 (0.12 to 0.40)
Initiated higher biological doses
 No0.47 (0.33 to 0.65)0.034
 Yes0.22 (0.12 to 0.40)
Dose escalation, %0.31 (0.17 to 0.56)0.57
Effect of IS on ADA detection
Assay
 ELISAs0.63 (0.50 to 0.79)0.035
 RIA0.36 (0.23 to 0.57)
  • ADA, anti-drug antibodies; ELISAs, Enzyme-linked immunosorbent assays; IS, immunosuppression; MTX, methotrexate; RA, Rheumatoid Arthritis; RIA, Radioimmuno assay; RR, Risk ratios.